trial
as of 2026-07-01Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
NCTId NCT00458211
at a glance
Phase 4 · Completed
Enrollment 40 (actual)
Sponsored by Bronx Psychiatric Center
Primary completion 2008-04
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2005-05
Primary completion
2008-04
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Bronx Psychiatric CenterLead Sponsor
Buffalo Psychiatric CenterCollaborator
Rochester Psychiatric CenterCollaborator
Investigators
3
Nigel Bark, MDPrincipal Investigator
Jeffrey Grace, MDPrincipal Investigator
Steven Schwarzkopf, MDPrincipal Investigator
Sites
2 total
Buffalo, United StatesThe Bronx, United States
Facts & assertions
4 sourced
Enrollment
40
Phase
PHASE4
Primary Completion Date
2008-04
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
indication
investigator